Blockchain Registration Transaction Record

Creative Biolabs AI Accelerates Multi-Receptor Agonist Design

Creative Biolabs upgrades AI platform for computational design of multi-receptor agonists, accelerating GLP-1/GIP/GCGR therapies with improved half-life and ADMET prediction.

This news matters because it addresses a critical bottleneck in developing next-generation metabolic therapies for obesity and diabetes. By dramatically reducing the time and cost of designing multi-receptor agonists—while improving stability and selectivity—Creative Biolabs' platform could accelerate the arrival of more effective, longer-lasting treatments with fewer side effects, potentially transforming care for millions of patients worldwide.